Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2021-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于会计差错更正专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed explanation regarding accounting error corrections and changes in accounting policies for Shenzhen Haiwang Bioengineering Co., Ltd. It references specific accounting standards (Enterprise Accounting Standards No. 28), regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial statement adjustments for multiple years (2017, 2018, 2019, and 2020). The document includes tables showing adjustments to balance sheets, income statements, and notes to financial statements. It also mentions an audit firm and an audit report previously issued. The content is focused on the correction of prior period accounting errors and the impact on financial statements, which is typical of an Audit Report or Information document rather than a full Annual Report or Interim Report. The document is substantive and contains detailed financial data and analysis related to accounting corrections, not merely an announcement or certification. Therefore, the most appropriate classification is Audit Report / Information (AR).
2021-04-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1235 characters) from Shenzhen Haiwang Bioengineering Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard issued by the Ministry of Finance. It explains the reasons for the change, the previous and new accounting policies, the effective date, and the impact on the company. There are no financial statements or detailed financial data presented, and the document serves to inform stakeholders about the accounting policy change. It is not a full audit report or annual/interim report, nor is it a certification or regulatory filing. Given the short length and nature of the content, this fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about accounting policy changes without detailed financial data or audit opinions.
2021-04-26 Chinese
关于前期会计差错更正及追溯调整的公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the correction of prior accounting errors and retrospective adjustments. It references regulatory oversight by the China Securities Regulatory Commission Shenzhen Bureau and cites specific accounting standards (Enterprise Accounting Standards No. 28) and disclosure rules. The document includes detailed financial data adjustments for multiple years (2017, 2018, 2019), including balance sheet and income statement items, notes to financial statements, and auditor opinions. It is not a full annual or interim report but a standalone disclosure focused on audit-related corrections and restatements. The presence of auditor opinions and detailed accounting corrections aligns with the definition of an Audit Report / Information filing rather than a full Annual Report or Interim Report. The document length is substantial and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2021
2021-04-26 Chinese
关于担保延续构成对外担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the continuation of guarantees provided to an external party (Changsha Haiwang Pharmaceutical Co., Ltd.) following a change in ownership and the resulting external guarantee obligations. It details the guarantee amounts, reasons for continuation, risk assessments, and approvals from the board and supervisory committee. The document does not contain financial statements or detailed financial performance data but focuses on the guarantee extension and related corporate governance matters. It is not a full annual or interim report, audit report, earnings release, or other financial report. It is also not a simple notice of dividend, share issue, or voting results. The content fits the category of a regulatory announcement about external guarantees, which is best classified under Regulatory Filings (RNS). The document length is under 5,000 characters and is a detailed announcement rather than a report publication announcement (RPA). Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-04-26 Chinese
关于回购注销已获授未解锁限制性股票的减资公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the repurchase and cancellation of restricted shares that have been granted but not unlocked. It details the reduction in registered capital due to this repurchase and cancellation, referencing relevant company law and notifying creditors of their rights. The content focuses on a capital change event related to share repurchase and cancellation, not a full financial report or earnings release. The document length is short (833 characters) and it is an announcement of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2021-04-26 Chinese
关于回购注销未达到第二期解锁条件已获授但尚未解锁限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the repurchase and cancellation of restricted shares that have not met the second unlocking condition. It details the reasons, quantities, prices, and procedures related to the repurchase and cancellation of restricted stock under the 2018 restricted stock incentive plan. The document includes board and supervisory committee meeting resolutions, independent director opinions, and legal opinions. It is a formal disclosure about a share repurchase and cancellation event, not a financial report or earnings release. The content focuses on capital structure changes due to share repurchase and cancellation of restricted shares, which fits the category of Transaction in Own Shares (POS). The document length is over 5,000 characters and contains detailed information about the transaction, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is POS.
2021-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.